ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rituximab

Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.

Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.

Drug pageRituximab: every studyMany companies study it; this page follows only the 124 they lead. All 1,284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2007124 company-led studies, 6 open or runningNext primary completion: Oct 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only781 open or runningphase 4since Jan 18, 2007Apr 1, 2003none ahead
SymBio Pharmaceuticalsits history only50 open or runningphase 3since Dec 10, 2017Nov 18, 2008none ahead
AbbVieits history only40 open or runningphase 3since Jun 9, 2014Apr 20, 2012none ahead
AstraZenecaits history only42 open or runningphase 4since Aug 23, 2023Apr 8, 2016Oct 31, 2028phase 2 · NCT05951959
Biogenits history only40 open or runningphase 4since Aug 23, 2004Mar 31, 2003none ahead
Takedaits history only40 open or runningphase 3since Apr 7, 2006Jun 11, 2004none ahead
Biocadits history only30 open or runningphase 3since Oct 3, 2012Oct 3, 2012none ahead
Celltrionits history only30 open or runningphase 1since Feb 8, 2012Feb 8, 2012none ahead
Favrilleits history only30 open or runningphase 3since Aug 4, 2004Aug 4, 2004none ahead
GlaxoSmithKlineits history only20 open or runningphase 3since Oct 13, 2017Dec 14, 2015none ahead
Bayer10 open or runningphase 2since Jul 8, 2004Jul 8, 2004none ahead

Also a collaborator on its studies: ICON Clinical Research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, Roche Pharma and Chiron.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2004First study: phase 2 study in LeukemiaFirst studyNCT00086775 · United States
  2. Jan 29, 2026Named rituximabINNProposed as its International Nonproprietary Name in WHO's List 134 · before, MK-8808

TargetBeta

MS4A1 →read by rule
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

The one study Bayer leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00086775Leukemia · United States2CompletedJun 2005

How it is read

Names in the registry

  • “Rituximab”, 104 entries
  • “rituximab”, 34 entries
  • “rituximab [MabThera/Rituxan]”, 23 entries
  • “Rituximab SC”, 2 entries
  • “MK-8808”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.